

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6645210

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SOPHIE CARAYON	02/17/2020
OTMANE BOUSSIF	02/03/2020
RECEIVING PARTY DATA	
Name:	SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
Street Address:	1 AVENUE PIERRE BROSSOLETTE
City:	CHILLY-MAZARIN
State/Country:	FRANCE
Postal Code:	91380
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	61453275
Application Number:	61537243
Application Number:	61557635
Application Number:	14003496
Application Number:	15206045
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	jana.ettienne@sanofi.com
Correspondent Name:	JANA ETTIENNE
Address Line 1:	55 CORPORATE DRIVE - MAIL CODE: 55A-525
Address Line 4:	BRIDGEWATER, NEW JERSEY 08807
ATTORNEY DOCKET NUMBER:	US2011/027
NAME OF SUBMITTER:	JANA ETTIENNE
SIGNATURE:	/Jana Ettienne/
DATE SIGNED:	04/06/2021
Total Attachments: 6	
source=Executed_FR_Inventors Boussif and Carayon#page1.tif	

source=Executed_FR_Inventors Boussif and Carayon#page2.tif
source=Executed_FR_Inventors Boussif and Carayon#page3.tif
source=Executed_FR_Inventors Boussif and Carayon#page4.tif
source=Executed_FR_Inventors Boussif and Carayon#page5.tif
source=Executed_FR_Inventors Boussif and Carayon#page6.tif

ASSIGNMENT

For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, the undersigned joint Inventors, each individually assign to **SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT**, a corporation formed under the laws of France and having a principal place of business at 1 avenue Pierre Brossolette, 91380 Chilly-Mazarin, France, and its successors, transferees, and assignees (collectively the "Assignee"), all of our individual and joint rights, titles, and interests throughout the world in the subject matter (the "Subject Matter") disclosed or claimed in the patents and applications listed in Schedule A (the "Patents and Applications").

This Assignment, effective as of 16 March 2011 assigns (a) the Application(s) and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region, (b) the right to claim priority based on and the benefit of the filing date of any of the Patents, Applications, and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee's name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.

We will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and


documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

Signed at Paris, France on this 17 day of February, 2020.
(City, State and Nation)

Signature:

Inventor's Name:

Mailing Address:


Sophie CARAYON
c/o SANOFI, Département Brevets
54 rue La Boétie
75008 Paris
France

Witnessed by:

Signature

Printed Name


Belicia RORTAIS



Signature

Printed Name

Sophie GRAULT



Signed at Basel, Switzerland on this 30th day of February, 2020.
(City, State and Nation)

Signature:

Inventor's Name:

Mailing Address:

Othmane BOUSSIF
33 rue Anatoile Celle,
Chaponost, 69630
France

Witnessed by:

Magdalena Obarzanek-Fojt
Signature


MAGDALENA OBARZANEK-FOJT
Printed Name

Eleonora Toffoli
Signature

ELEONORA TOFFOLI
Printed Name

**ASSIGNMENT OF RIGHTS ACCEPTED BY SANOFI-AVENTIS RECHERCHE &
DEVELOPPEMENT**

Signed at Paris on this 18 day of February, 2020.
(City, State and Nation)

By: 

Name: Brigitte CARION-TARAVELLA

Title: Leader of Biologics Patents France

SCHEDULE A

<u>Pat./Pub. No.</u>	<u>App. No.</u>	<u>Country</u>	<u>Filing Date</u>	<u>Title</u>
AR085911A1	P120100851	AR	15 Mar 2012	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
2686014	12711509.5	EP	15 Mar 2012	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
3235508	17151270.0	EP	12 Jan 2017	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
	1162177	FR	21 Dec 2011	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
	14105843.2	HK	19 Jun 2014	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
	18105427.2	HK	25 Apr 2018	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
P2014-0510730A	2013-558155	JP	15 Mar 2012	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
2016-196485	2016-118649	JP	15 Jun 2016	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
2017-137336	2017-55301	JP	22 Mar 2017	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
2019-059762	2018-229677	JP	07 Dec 2018	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
WO2012/125775	PCT/US2012/029147	PCT	15 Mar 2012	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN

<u>Pat./Pub. No.</u>	<u>App. No.</u>	<u>Country</u>	<u>Filing Date</u>	<u>Title</u>
	101108867	TW	15 Mar 2012	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
201731529	106101119	TW	13 Jan 2017	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
	61/453,275	USA	16 Mar 2011	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
	61/537,243	USA	21 Sep 2011	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
	61/557,635	USA	09 Nov 2011	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
US-2013-0344074-A1	14/003,496	USA	06 Sep 2013	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN
US-2017-0029498-A1	15/206045	USA	08 Jul 2016	USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN